IBDEI09O ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4473,0)
 ;;=173.81^^37^434^1
 ;;^UTILITY(U,$J,358.3,4473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4473,1,3,0)
 ;;=3^173.81
 ;;^UTILITY(U,$J,358.3,4473,1,4,0)
 ;;=4^BCCA SKIN,SITE NEC
 ;;^UTILITY(U,$J,358.3,4473,2)
 ;;=^340488
 ;;^UTILITY(U,$J,358.3,4474,0)
 ;;=173.82^^37^434^19
 ;;^UTILITY(U,$J,358.3,4474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4474,1,3,0)
 ;;=3^173.82
 ;;^UTILITY(U,$J,358.3,4474,1,4,0)
 ;;=4^SCCA SKIN,SITE NEC
 ;;^UTILITY(U,$J,358.3,4474,2)
 ;;=^340489
 ;;^UTILITY(U,$J,358.3,4475,0)
 ;;=173.89^^37^434^20
 ;;^UTILITY(U,$J,358.3,4475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4475,1,3,0)
 ;;=3^173.89
 ;;^UTILITY(U,$J,358.3,4475,1,4,0)
 ;;=4^SKIN CANCER-OTHER,SITE NEC
 ;;^UTILITY(U,$J,358.3,4475,2)
 ;;=^340490
 ;;^UTILITY(U,$J,358.3,4476,0)
 ;;=174.9^^37^434^3
 ;;^UTILITY(U,$J,358.3,4476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4476,1,3,0)
 ;;=3^174.9
 ;;^UTILITY(U,$J,358.3,4476,1,4,0)
 ;;=4^BREAST CANCER
 ;;^UTILITY(U,$J,358.3,4476,2)
 ;;=^267202
 ;;^UTILITY(U,$J,358.3,4477,0)
 ;;=180.9^^37^434^4
 ;;^UTILITY(U,$J,358.3,4477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4477,1,3,0)
 ;;=3^180.9
 ;;^UTILITY(U,$J,358.3,4477,1,4,0)
 ;;=4^CERVICAL CANCER
 ;;^UTILITY(U,$J,358.3,4477,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,4478,0)
 ;;=183.0^^37^434^16
 ;;^UTILITY(U,$J,358.3,4478,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4478,1,3,0)
 ;;=3^183.0
 ;;^UTILITY(U,$J,358.3,4478,1,4,0)
 ;;=4^OVARIAN CANCER
 ;;^UTILITY(U,$J,358.3,4478,2)
 ;;=^267224
 ;;^UTILITY(U,$J,358.3,4479,0)
 ;;=185.^^37^434^18
 ;;^UTILITY(U,$J,358.3,4479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4479,1,3,0)
 ;;=3^185.
 ;;^UTILITY(U,$J,358.3,4479,1,4,0)
 ;;=4^PROSTATE CANCER
 ;;^UTILITY(U,$J,358.3,4479,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,4480,0)
 ;;=187.9^^37^434^13
 ;;^UTILITY(U,$J,358.3,4480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4480,1,3,0)
 ;;=3^187.9
 ;;^UTILITY(U,$J,358.3,4480,1,4,0)
 ;;=4^MALE GENITAL CANCER
 ;;^UTILITY(U,$J,358.3,4480,2)
 ;;=^267252
 ;;^UTILITY(U,$J,358.3,4481,0)
 ;;=193.^^37^434^21
 ;;^UTILITY(U,$J,358.3,4481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4481,1,3,0)
 ;;=3^193.
 ;;^UTILITY(U,$J,358.3,4481,1,4,0)
 ;;=4^THYROID CANCER
 ;;^UTILITY(U,$J,358.3,4481,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,4482,0)
 ;;=195.0^^37^434^7
 ;;^UTILITY(U,$J,358.3,4482,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4482,1,3,0)
 ;;=3^195.0
 ;;^UTILITY(U,$J,358.3,4482,1,4,0)
 ;;=4^HEAD/FACE/NECK CANCER
 ;;^UTILITY(U,$J,358.3,4482,2)
 ;;=^267306
 ;;^UTILITY(U,$J,358.3,4483,0)
 ;;=199.1^^37^434^15
 ;;^UTILITY(U,$J,358.3,4483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4483,1,3,0)
 ;;=3^199.1
 ;;^UTILITY(U,$J,358.3,4483,1,4,0)
 ;;=4^METASTATIC CANCER
 ;;^UTILITY(U,$J,358.3,4483,2)
 ;;=^87705
 ;;^UTILITY(U,$J,358.3,4484,0)
 ;;=202.80^^37^434^12
 ;;^UTILITY(U,$J,358.3,4484,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4484,1,3,0)
 ;;=3^202.80
 ;;^UTILITY(U,$J,358.3,4484,1,4,0)
 ;;=4^LYMPHOMA
 ;;^UTILITY(U,$J,358.3,4484,2)
 ;;=^87701
 ;;^UTILITY(U,$J,358.3,4485,0)
 ;;=208.90^^37^434^9
 ;;^UTILITY(U,$J,358.3,4485,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4485,1,3,0)
 ;;=3^208.90
 ;;^UTILITY(U,$J,358.3,4485,1,4,0)
 ;;=4^LEUKEMIA w/o REMISSION
 ;;^UTILITY(U,$J,358.3,4485,2)
 ;;=^336874
 ;;^UTILITY(U,$J,358.3,4486,0)
 ;;=208.91^^37^434^8
 ;;^UTILITY(U,$J,358.3,4486,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4486,1,3,0)
 ;;=3^208.91
 ;;^UTILITY(U,$J,358.3,4486,1,4,0)
 ;;=4^LEUKEMIA w/ REMISSION
 ;;^UTILITY(U,$J,358.3,4486,2)
 ;;=^267576
 ;;^UTILITY(U,$J,358.3,4487,0)
 ;;=996.80^^37^435^1
